1215074-41-1

Basic information

• Product Name: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine
• Synonyms: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine
• CAS NO: 1215074-41-1
• Molecular Formula: C₇H₂BrCl₂N₃
• Molecular Weight: 278.93
• Mol File: 1215074-41-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 323.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.946±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -3.17±0.30(Predicted)
• CAS DataBase Reference: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(1215074-41-1)
• EPA Substance Registry System: 7-Bromo-2,4-dichloropyrido[3,2-d]pyrimidine(1215074-41-1)

Safety Data

• Hazardous Substances Data: 1215074-41-1(Hazardous Substances Data)

Upstream product

• 870997-85-6 3-amino-5-bromo-pyridine-2-carboxylic acid 
• 669066-89-1 3-amino-5-bromopyridine-2-carboxylic acid amide 
• 573675-25-9 5-bromo-3-nitropyridine-2-carbonitrile 
• 1215074-37-5 7-bromopyrido[3,2-d]pyrimidine-2,4-diol 
• 1215074-37-5 7-bromo-1H-pyrido[3,2-d]pyrimidine-2,4-dione 
• 1334405-60-5 ethyl 3-amino-5-bromopyridine-2-carboxylate 

Downstream Products

• 1374203-79-8 N,N-dimethyl-4-{3-[4-(4-morpholin-4-yl-7-pyrimidin-5-yl-pyrido[3,2-d]-pyrimidin-2-yl)-phenyl]-ureido}-benzamide 
• 1557084-70-4 C₂₉H₂₉Cl₃N₈O₅ 

Relevant articles and documents

PYRIDOPYRIMIDINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

CD73 INHIBITORS

Disclosed are compounds that are inhibitors of CD73 and are useful in treating CD73-associated diseases or conditions, and compositions containing the compounds.

A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787

In this work we describe the optimization of a lead compound based on the quinazoline template to give a new series of potent pyrido[3,2-d]pyrimidines as histamine H4 receptor antagonists. The pyrido[3,2-d]pyrimidine ligands have significantly reduced hERG binding compared to clinical stage compound PF-3893787 while showing good affinities at the human and rodent histamine receptors. The receptor residence time of several of these new compounds was determined for the human H4R and compared with JNJ7777120 and PF-3893787. The pyrido[3,2-d]pyrimidines showed residence times lower than JNJ7777120 but comparable to the residence time of PF-3893787. Overall, the pyrido[3,2-d]pyrimidines show an excellent in vitro profile that warrants their further investigation in relevant models of human disease.